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Abstract: The objective of this study was to assess the effectiveness of a stroke clinic in stroke prevention
and progression of cerebral microbleeds (CMB). We conducted a retrospective observational study of
patients who visited a stroke clinic between January 2011 and March 2017. Susceptibility-weighted
imaging (SWI) MRI studies were obtained at baseline and follow-up visits to identify new infarctions
and CMB progression. Patients with CMB who also underwent brain computed tomography (CT)
imaging were identified and their cerebral arterial calcification was quantified to evaluate the
relationship between the extent of intracranial calcification and CMB burden. A total of 64 stroke
patients (mean age 73.1 ± 11.0, 47% males) had CMB on baseline and follow-up MRI studies. During a
mean follow-up period of 22.6 months, four strokes occurred (4/64, 6%; 3 ischemic, 1 hemorrhagic),
producing mild neurological deficit. Progression of CMB was observed in 54% of patients with
two MRIs and was significantly associated with length of follow-up. Subjects with intracranial
calcification score > 300 cm3 had higher CMB count than those with scores <300 cm3 at both baseline
(12.6 ± 11.7 vs. 4.9 ± 2.2, p = 0.02) and follow-up (14.1 ± 11.8 vs. 5.6 ± 2.4, p = 0.03) MRI evaluations.
Patients with CMB had a relatively benign overall clinical course. The association between CMB
burden and intracranial calcification warrants further study.
Keywords: cerebral microbleeds; infarction; stroke prevention; cerebrovascular disease/stroke;
CT; MRI
1. Introduction
Cerebral microbleeds (CMB) are MRI-demonstrable lesions corresponding to focal hemosiderin
depositions that are indicative of underlying microhemorrhages [1]. These lesions persist with time, which
allows the evaluation of cumulative microbleed burden. CMB detection is clinically relevant given that
microbleeds may serve as a biomarker for increased risk of ischemic as well as hemorrhagic stroke [2].
CMB frequently coexist with ischemic stroke syndromes. This has been previously referred to as “mixed
cerebrovascular disease”, a term which combines clinical and subclinical disease with both ischemic and
hemorrhagic elements [3,4]. As a result, anticoagulation decisions and the need to prevent ischemic stroke,
while not provoking hemorrhagic stroke or worsening CMB, can be challenging for the stroke clinician [4–8].
Accordingly, we hypothesized that the management of CMB patients by a stroke neurologist attentive
to the complexities of mixed cerebrovascular disease would result in effective stroke prevention. In the
current study, we investigated stroke events and the progression of CMB in patients who were initially
evaluated and managed in a stroke clinic. We attempted to identify biomarkers for progression of CMB,
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using a recently proposed conceptual framework in which CMB development is associated with arterial
abnormalities related to dysfunctional regulation of cerebral blood flow [9]. We therefore analyzed clinical
outcomes and intracranial calcification in patients with CMB.
2. Results
2.1. Patients
Of the 348 patients who visited the stroke clinic at the UC Irvine Medical Center between January
2011 and March 2017, 66 (19%) patients had CMB on MRI; 64 of these had a follow-up visit and were
included in this study. The mean age was 73.1 ± 11.0 years. Forty-seven percent were males. The ethnic
distribution was 48% White, 34% Asian, 14% Hispanic, and 3% Black. The clinical diagnoses of the
patients were ischemic stroke (n = 33, 52%), cerebral amyloid angiopathy (n = 11, 17%), vascular
dementia (n = 10, 16%), intracerebral hemorrhage (n = 4, 6%), and other conditions (n = 6, 9%). The most
common probable cause of CMB was hypertension alone (n = 31, 48%), followed by the combination of
hypertension and chronic kidney disease (n = 11, 17%), hypertension and cerebral amyloid angiopathy
(n = 9, 14%), and hypertension with chronic kidney disease and cerebral amyloid angiopathy (n = 1, 2%).
2.2. Stroke Outcome at Follow-Up
The 64 patients were followed for an average of 22.6 months. During this time, four clinical
strokes occurred (3 ischemic strokes, 1 hemorrhagic stroke; 1.7% annualized ischemic stroke rate; 0.6%
annualized hemorrhagic stroke rate). Three strokes were related to mild but permanent neurological
deficit (1 facial weakness, 1 hemiparesis, 1 cognitive decline). All patients were treated with strict
attention to blood pressure control and judicious use of antithrombotic medications.
2.3. CMB Progression on Follow-Up MRI Studies
Follow-up MRI was performed in 46 of the 64 patients. The mean interval between initial and
follow-up MRI was 26.5 months (range: 1 to 77). Progression of CMB was observed in 25 patients
(54%), with 14 having a CMB count increase of ≥3. Figure 1 is an example of baseline and follow-up
axial susceptibility-weighted imaging (SWI) showing CMB count progression in one patient. Among the
46 patients who had follow-up MRIs, there were 26 males and 20 females; there was no observable
association between sex and CMB progression in our study population (57% of males with no CMB
progression as compared to 56% with CMB progression). Age, vascular risk factors, chronic kidney disease,
cerebral amyloid angiopathy, and use of antithrombotics showed no association with CMB progression
(Table 1). Mean MRI follow-up interval was significantly associated with CMB progression (18.7 (no
progression) vs. 33.6 (progression) months, p = 0.003, Table 1). The majority of patients who had evidence of
stroke between the initial and follow-up visits (3/4) had progression of their CMB count on follow-up MRI.
Table 1. Demographic factors and stroke events in 46 patients with and without cerebral microbleed
(CMB) progression.
CMB No
Progression (n = 21)
CMB Progression
(n = 25) p-Value
Mean ± SD Mean ± SD
Age 73.3 ± 12.1 73.7 ± 10.4 0.90
Clinical follow-up interval (months) 24.2 ± 23.3 29.1 ± 22.1 0.46
MRI follow-up interval (months) 18.6 ± 12.1 33.1 ± 18.8 0.003
N (%) N (%)
Male 12 (57) 14 (56) 1.00
Race White 6 (29) 14 (56)
0.08 (White vs.
Other)
Asian 8 (38) 9 (36)
Hispanic 5 (24) 2 (8)
Black 2 (10) 0 (0)
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Table 1. Cont.
CMB No
Progression (n = 21)
CMB Progression
(n = 25) p-Value
Hypertension 14 (67) 22 (88) 0.15
Diabetes 5 (24) 7 (28) 1.00
Hyperlipidemia 13 (62) 15 (60) 1.00
Smoking 3 (14) 4 (16) 1.00
Chronic kidney disease 5 (24) 8 (32) 0.22
Cerebral amyloid angiopathy 3 (14) 6 (24) 0.48
Use of antithrombotics 13 (62) 15 (60) 1.00
Stroke event at follow-up 1 (5) 3 (12) 0.61
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Figure 1. Baseline and follow-up axial susceptibility-weighted images showing CMB count 
progression. Axial SWI from the same individual showing cerebral microbleeds (CMB) in two sections 
at the initial visit shown in (A,C), and at the follow-up visit 36 months later shown in (B,D). (A) Left 
lobar microbleed (yellow arrow). (B) New right thalamic and left lobar microbleeds (white arrows). 
(C) Right cerebellar microbleed (yellow arrow). (D) New cerebellar microbleeds (white arrows). 
2.4. Intracranial Calcification 
The assessment of calcification with computed tomography (CT) was performed in 26 patients. 
Calcification scores ranged from 32 to 4021 cm3 with a mean of 877. Patients with intermediate 
calcification scores (300–1000 cm3) had mean CMB counts similar to the patients with high 
calcification scores (>1000 cm3). Excluding one patient with many but not quantifiable CMB on both 
initial and follow-up, these two groups had higher CMB counts than those with scores <300 cm3 in 
both the initial (12.6 ± 11.7 vs. 4.9 ± 2.2, p = 0.02) and follow-up (14.1 ± 11.8 vs. 5.6 ± 2.4, p = 0.03) MRI 
studies (Table 2, Figure 2). 
  
Figure 1. Baseline and follow-up axial susceptibility-weighted imaging showing CMB count progression.
Axial SWI from the same individual showing cerebral microbleeds (CMB) in two sections at the initial
visit shown in (A,C), and at the follow-up visit 36 months later shown in (B,D). (A) Left lobar microbleed
(yellow arrow). (B) New right thalamic and left lobar microbleeds (white arrows). (C) Right cerebellar
microbleed (yellow arrow). (D) New cerebellar microbleeds (white arrows).
2.4. Intracranial Calcification
The assessment of calcification with computed tomography (CT) was performed in 26 patients.
Calcification scores ranged from 32 to 4021 cm3 with a mean of 877. Patients with intermediate
calcification scores (300–1000 cm3) had mean CMB counts si ilar to the patients with high calcification
scores (>1000 cm3). Excluding one patient with many but not quantifiable CMB on both initial and
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follow-up, these two groups had higher CMB counts than those with scores <300 cm3 in both the
initial (12.6 ± 11.7 vs. 4.9 ± 2.2, p = 0.02) and follow-up (14.1 ± 11.8 vs. 5.6 ± 2.4, p = 0.03) MRI studies
(Table 2, Figure 2).
Table 2. Vascular calcification scores and cerebral microbleed (CMB) counts in 26 patients.
Calcification Score (cm3) Number of CMB at Initial Scan Number of CMB at Follow-Up Scan
Mean ± SD
Range
No. of Subjects
Mean ± SD
Range
No. of Subjects
<300
Range 32–286
4.9 ± 2.2
1–7
(n = 8)
5.6 ± 2.4
3–8
(n = 5)
300–1000
Range 309–770
12.3. ± 12.4
0–32
(n = 9) †
13.7 ± 13.5
0–32
(n = 9) †
>1000
Range 1159–4021
13.0 ± 11.7
3–37
(n = 8)
15.0 ± 8.6
7–27
(n = 4)
p-value for difference in low vs.
intermediate and high groups 0.02 0.03
† One patient with many but not quantifiable CMB on both initial and follow-up MRI was not included in
the calculation.
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Figure 2. Axial non-contrast head computed tomography (CT) scans comparing patients with a high 
and low burden of calcification. Head CT obtained from a patient with a “high” burden of calcification 
(A) within the cavernous carotid (denoted by the arrow), which measured 3093 cm3. For comparison, 
axial non-contrast head CT of a patient with a “low” burden of calcification (B) within the cavernous 
carotid, which measured 106 cm3. 
3. Discussion 
In this cohort of 64 patients with CMB followed in a stroke clinic over an average two-year 
period. We demonstrate that (1) the overall clinical course of patients with underlying CMB was 
relatively benign, (2) a significant proportion of the 46 patients who had baseline and follow-up MRIs 
(54%) had progression in their CMB count at their follow-up MRI, (3) a higher CMB count at follow-
up was significantly related to length of follow-up and not with demographic or stroke risk factors, 
and (4) a higher cerebral arterial calcification score was significantly associated with a higher CMB 
count. 
Previous studies have shown that CMB tend to persist with time on MRI using high-field and 
thin-slice parameters in patients who were followed for up to nine years [10,11]. Here we have shown 
that not only do CMB persist after two years, but that new microhemorrhages occur frequently 
during that time frame, thus indicating the potential need to conduct follow-up MRI studies at shorter 
intervals. At follow-up, 6% (4/64) of the patients reported having had a clinical stroke with mild 
neurologic deficits. Out of these four patients, three had an increase in the number of their CMB on 
follow-up MRI. Although this finding was not statistically significant, it does suggest a vulnerability 
Figure 2. Axial non-contrast head computed tomography (CT) scans comparing patients with a high
and low burden of calcification. Head CT obtained from a patient with a “high” burden of calcification
(A) within the cavernous carotid (denoted by the arrow), which measured 3093 cm3. For comparison,
axial non-contrast head CT of a patient with a “low” burden of calcification (B) within the cavernous
carotid, which measured 106 cm3.
3. Discussion
We describe a cohort of 64 patients with CMB followed in a stroke clinic over an average period of
two years. We demonstrate that (1) the overall clinical course of patients with underlying CMB was
relatively benign, (2) a significant proportion of the 46 patients who had baseline and follow-up MRIs
(54%) had progression in their CMB count at their follow-up MRI, (3) a higher CMB count at follow-up
was significantly related to length of follow-up and not with demographic or stroke risk factors, and (4)
a higher cerebral arterial calcification score was significantly associated with a higher CMB count.
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Previous studies have shown that CMB tend to persist with time on MRI using high-field and
thin-slice parameters in patients who were followed for up to nine years [10,11]. Here we have shown
that not only do CMB persist after two years, but that new microbleeds occur frequently during that
time frame, thus indicating the potential need to conduct follow-up MRI studies at shorter intervals.
At follow-up, 6% (4/64) of the patients reported having had a clinical stroke with mild neurologic
deficits. Out of these four patients, three had an increase in the number of their CMB on follow-up
MRI. Although this finding was not statistically significant, it does suggest a vulnerability to stroke in
patients with CMB progression detected on MRI. Indeed, the presence of CMB has been associated
with an increased rate of ischemic and hemorrhagic strokes [2].
The literature suggests that the presence of four or more microbleeds may increase the risk of
cognitive decline and dementia [12,13]. Most patients in this study did not have a worsening of their
cognitive function or signs of neurologic impairment at their follow-up visit in the clinic, suggesting
that the increase in CMB count in this patient population with pre-existing microbleeds was essentially
subclinical. Indeed, the majority of patients with CMB at baseline had a benign overall clinical
course during the study period. They were treated with close attention to tight control of their blood
pressure, and this has been shown to reduce the risk of incident strokes and dementia in patients with
hypertension [14].
We also showed that intracerebral arterial calcification is associated with CMB, with higher vascular
calcification scores obtained in patients with a larger number of CMB. Some studies have reported
more extensive vascular calcification in both intracranial and extracranial arteries (internal carotid and
coronary arteries) in patients with cerebral small vessel disease, including those with CMB [15–17].
Vascular calcification could disrupt the ability of brain arterioles to compensate for changes in
systemic blood pressure, leading to a rise in the intraluminal pressure within the microvasculature
and subsequent erythrocyte extravasation contributing to microhemorrhage formation [9,18–20].
The potential mechanisms relating vascular calcification and CMBs are complex and further studies
are needed to gain a better understanding.
This study has limitations. The observational retrospective design of the study precludes making
causal associations between the presence of intracerebral arterial calcification and CMB. The follow-up
time was longer in patients showing CMB progression (33 vs. 19 months); progression of CMB
might develop with longer follow-up. In addition, a larger sample size is needed to draw more
definitive conclusions about clinical outcomes such as stroke and cognitive function associated with
CMB progression. Existing data in the literature suggests associations between CMB presence and
cerebral amyloid angiopathy [21], hypertension [22], and chronic kidney disease [23]. In our study,
we report the comparison of the progression of CMB in association with the various vascular risk
factors. With only 21 and 25 subjects in the two groups (no CMB progression and CMB progression,
respectively), we had low statistical power to detect significant differences even for hypertension,
which showed the greatest difference in proportions (67% of subjects with no CMB progression had
hypertension as compared to 88% of subjects with both hypertension and CMB progression).
4. Materials and Methods
4.1. Standard Protocol Approvals, Registrations, and Patient Consents
This study was approved by the Institutional Review Board at University of California, Irvine
(approval code: 2017-3590, approval date: 17 May 2018). Requirements for patient consents were
waived due to the retrospective design of the study.
4.2. Patient Selection
We identified patients who visited a stroke prevention clinic at the UC Irvine Medical Center
between January 2011 and March 2017. Patients who had CMB on susceptibility-weighted imaging
magnetic resonance imaging were included for this analysis. Medical records were reviewed to
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obtain information about age, sex, vascular risk factors (hypertension, smoking, hyperlipidemia,
diabetes), medications (antithrombotic and cholesterol-lowering medications), and history of chronic
kidney disease and coronary artery disease. We determined the likely underlying etiology of CMB in
each patient, e.g., hypertension, cerebral amyloid angiopathy, chronic kidney disease, and secondary
microbleeds (hemorrhagic infarction or microinfarction) [9,21]. The timing of the follow-up visit was
determined by the attending stroke physician.
4.3. MRI and CMB Identification
Baseline and follow-up MRIs were studied at initial and follow-up clinic visits set by the stroke
physician. MRI examinations were conducted using a 1.5-tesla or 3-tesla scanner and images were
obtained using the susceptibility-weighted imaging sequence. For the 1.5T MRI scans, we used the
following parameters: repetition = 49 ms, echo time = 40 ms, flip angle = 15 degrees. For the 3T scans,
the parameters were: repetition time = 27 ms, echo time = 20 ms, flip angle = 15 degrees. The slice
thickness was 2 mm and the interlayer spacing was 0 mm for both types of scans. Susceptibility-weighted
imaging was individually examined by an experienced radiologist and by a neurologist who were
both blinded to the participants’ clinical information. Definite CMB were identified as small,
round, well-defined, hypointense lesions on SWI, 2–10 mm in size, and that are not well seen
on a T2 sequence. They were distinguished from microbleed mimics such as signals from air-bone
interfaces, mineralization in globi pallidi or dentate nuclei, hemorrhage from a specific secondary
cause, and partial volume artifacts using Microbleed Anatomic Rating Scale criteria [22]. The number
of CMB and the coexistence of cortical superficial siderosis were analyzed. The CMB counts obtained
from the follow-up MRI scans were compared to the baseline CMB counts. Individuals with elevated
CMB counts at follow-up were classified as having CMB progression. We compared individuals with
and without CMB progression to identify potential associations between demographic and clinical risk
factors and CMB development.
4.4. Computed Tomography (CT) Interpretation and Cerebral Arterial Calcification Score
The cerebral arterial calcification score was obtained by conducting CT imaging. For analysis
of the CT images, all raw Digital Imaging and Communications in Medicine (DICOM) files from the
axial reconstruction were downloaded, anonymized, and converted to NifTi format. For each CT
volume, a threshold-based technique was used to manually generate regions of interest for calcification
within the intracranial vasculature using the open-source 3D Slicer platform version 4.8 [23]. Vessels of
interest were the internal carotid, external carotid, and vertebral arteries as well as the basilar artery.
A custom Python script was written to determine the total number of voxels containing calcification
and converted to physical volume (cm3) through multiplication by voxel size contained in the original
DICOM header. All masks were visually inspected for accuracy by a board-certified subspecialist
neuroradiologist. Total calcification scores were calculated by summing up the calcification physical
volumes in all arterial regions of interest per human brain. The subjects who underwent CT imaging
were stratified into tertiles based on their total calcification scores.
4.5. Clinical Outcomes
The primary outcome was the occurrence of ischemic or hemorrhagic stroke after the initial
evaluation of patients with CMB. Clinical stroke symptoms reported by the patients were compared with
radiologic abnormalities on MRI studies obtained at follow-up. MRI studies were used to characterize
the stroke as ischemic or hemorrhagic and the likely underlying mechanism. Our secondary outcome
was the progression of CMB, defined as an increase in the number of CMB detected on the follow-up
MRI compared with the initial MRI.
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4.6. Statistical Analysis
Descriptive statistics (means, standard deviations, proportions) were calculated for the overall
sample and stratified by the progression of CMB. For calculation of stroke incidence rates,
the person-years of follow-up for each participant was calculated from the initial visit to the follow-up
visit or the time of stroke, whichever came first. Group differences in the means of continuous variables
and in proportions of categorical variables were tested using t-tests and Fisher exact tests. Two-sided
p < 0.05 was considered statistically significant. Statistical analyses were performed using SAS software
version 9.4 for Windows (SAS Institute Inc., Cary, NC, USA).
5. Conclusions
In this stroke clinic-based study, we demonstrated that CMB presence was associated with an
overall benign clinical course. In addition, patients with higher cerebral arterial calcification scores
had a significantly greater CMB burden. Prospective longitudinal studies and pathology analyses are
needed to obtain a better understanding of the relationship between vascular calcification and CMB
formation, and to determine whether cerebral arterial calcification score may be useful in cerebral
microbleed risk prediction.
Author Contributions: Conceptualization, M.F. and A.-H.C.; methodology, M.F., A.-H.C., L.W., D.C., D.F., and P.C.;
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